ce
The NIOSH Hazardous Drug List
NIOSH LIST OF HAZARDOUS DRUGS IN HEALTHCARE SETTINGS 2024 TABLE 1
Table 1 contains drugs that have MSHI in the pack- age insert and/or meet the NIOSH definition of a hazardous drug and one or more of these criteria: • Are classified by the National Toxicology Program (NTP) as “known to be a human carcinogen.” • Are classified by the International Agency for Research on Cancer (IARC) as Group 1 “car- cinogenic to humans” or Group 2A “probably carcinogenic to humans.” Many of these drugs are cytotoxic, and many are hazardous to those workers who are actively trying to conceive, who are pregnant or may become preg- nant, and who are breastfeeding because the drugs may be excreted in breast milk. It should be noted that not all then drugs listed in Table are antineo- plastic drugs. Drugs reviewed for this update were
new drug approvals or received new safety-related warnings from FDA in the period from January 2014 through December 2015. Drugs underlined and in red font were added on the 2024 List Update. Table abbreviations and footnotes. AHFS = American Hospital Formulary Service; MSHI = manufacturer’s special handling information; NA = not available. * Drugs identified as IARC Group 2B “possibly carcinogenic to humans” or as NTP “reasonably anticipated to be a human carcinogen are listed in Table 1 because they have MSHI. Refer to Table 2 NIOSH List of Hazardous Drugs in Healthcare Settings 2024-Table 1.
Table 1-Cancer Classification Designation by Organization
Drug
AHFS Classification
MSHI
Biologics Li - cense Applica - tion
IARC and NTP Classification
ado-trastuzumab emtansine Antineoplastic agents
Yes Yes Yes Yes
Yes
altretamine amsacrine
Antineoplastic agents Antineoplastic agents Antineoplastic agents
No No No
IARC Group 2B*
arsenic trioxide
IARC Group 1 carcinogen. NTP “known to be a human carcinogen” IARC Group 2A carcinogen. NTP “reasonably anticipated. to be a human carcinogen” IARC Group 1 carcinogen; NTP “known to be human carcinogen”
azacitidine
Antineoplastic agents
Yes
No
azathioprine
Immunosuppressive agents; immunomodulatory agents; disease-modifying antirheu- matic drugs
Yes
No
belantamab mafodotin
Antineoplastic agents Antineoplastic agents Antineoplastic agents Antineoplastic agents Antineoplastic agents Antineoplastic agents Antineoplastic agents Antineoplastic agents Antineoplastic agents
Yes Yes Yes Yes Yes Yes Yes
No No No No No
belinostat
bendamustine
bleomycin bortezomib
IARC Group 2B*
brentuximab vedotin
Yes
busulfan
No No No
IARC Group 1 carcinogen
cabazitaxel capecitabine
Yes
Yes
CPhT CONNECT
www.cphtconnect.com 36
Made with FlippingBook - PDF hosting